| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 138 | 31% | 14% | 55% | 85% |
| 01 Jul 2018 - 31 Dec 2018 | 21 Jan 2019 | 52 | 48% | 30% | 22% | 75% |
| 01 Jan 2018 - 30 Jun 2018 | 26 Jul 2018 | 52 | 48% | 30% | 22% | 75% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
30 days from date of invoice
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
Payment terms are agreed up front with the supplier as part of the purchasing negotiations
Maximum contractual payment period agreed
120
All our suppliers have the possibility to resolve disputes via our Accounts payable team, or escalating to our Procurement Team if not satisfied
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Indivior EU Limited is a UK-registered company within the Indivior group, a specialty pharmaceutical business focused on treatments for opioid use disorder (OUD). Its stated nature of business is the manufacture of basic pharmaceutical products. The wider Indivior group develops evidence-based OUD treatments, including long-acting injectable buprenorphine therapies, and works with clinicians, policymakers and communities to expand access to treatment and reduce stigma around addiction. The group's headquarters and research centres are based in the United States, with this entity forming part of its UK operations. The trademark Indivior is registered to a related UK entity within the same corporate group.
Generated from the company's website and Companies House records. Sources: indivior.com · indivior.com